Hirtle Callaghan & Co LLC acquired a new stake in CVS Health Corp (NYSE:CVS) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 2,680 shares of the pharmacy operator’s stock, valued at approximately $176,000.
Several other large investors also recently bought and sold shares of the company. Bell Rock Capital LLC raised its holdings in shares of CVS Health by 764.0% in the fourth quarter. Bell Rock Capital LLC now owns 432 shares of the pharmacy operator’s stock worth $28,000 after buying an additional 382 shares during the period. Daiwa SB Investments Ltd. purchased a new stake in shares of CVS Health in the fourth quarter worth approximately $30,000. Acima Private Wealth LLC purchased a new position in CVS Health during the 4th quarter worth $33,000. Cornerstone Advisors Inc. increased its holdings in CVS Health by 71.6% during the 3rd quarter. Cornerstone Advisors Inc. now owns 508 shares of the pharmacy operator’s stock worth $40,000 after purchasing an additional 212 shares during the period. Finally, 1 North Wealth Services LLC purchased a new position in CVS Health during the 4th quarter worth $42,000. 84.55% of the stock is owned by institutional investors and hedge funds.
Several research analysts have commented on the company. Loop Capital set a $80.00 price objective on CVS Health and gave the stock a “hold” rating in a report on Wednesday, November 28th. Cantor Fitzgerald initiated coverage on CVS Health in a report on Monday, November 26th. They issued an “overweight” rating and a $96.00 price target on the stock. Goldman Sachs Group reiterated a “neutral” rating and issued a $87.00 price target on shares of CVS Health in a report on Thursday, November 29th. Evercore ISI started coverage on CVS Health in a research report on Wednesday, November 28th. They issued an “outperform” rating and a $89.00 price objective for the company. Finally, Wells Fargo & Co raised their price objective on CVS Health from $98.00 to $104.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 27th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and fifteen have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $84.18.
CVS Health (NYSE:CVS) last issued its quarterly earnings results on Wednesday, February 20th. The pharmacy operator reported $2.14 EPS for the quarter, topping the Zacks’ consensus estimate of $2.07 by $0.07. CVS Health had a positive return on equity of 17.49% and a negative net margin of 0.31%. The company had revenue of $54.42 billion during the quarter, compared to analysts’ expectations of $53.78 billion. During the same quarter in the previous year, the firm posted $1.92 EPS. The firm’s revenue was up 12.5% compared to the same quarter last year. As a group, equities research analysts expect that CVS Health Corp will post 6.8 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, May 3rd. Shareholders of record on Tuesday, April 23rd will be paid a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 3.58%. The ex-dividend date of this dividend is Monday, April 22nd. CVS Health’s dividend payout ratio (DPR) is 28.25%.
In related news, insider Larry J. Merlo sold 166,368 shares of the stock in a transaction on Tuesday, January 8th. The stock was sold at an average price of $69.04, for a total value of $11,486,046.72. Following the transaction, the insider now owns 496,577 shares of the company’s stock, valued at $34,283,676.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director C David Brown II bought 10,000 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The stock was acquired at an average cost of $53.18 per share, for a total transaction of $531,800.00. Following the acquisition, the director now directly owns 16,222 shares of the company’s stock, valued at $862,685.96. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 23,600 shares of company stock worth $1,270,896 and have sold 412,039 shares worth $27,326,012. 0.53% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: This story was first reported by Markets Daily and is the property of of Markets Daily. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://www.themarketsdaily.com/2019/03/15/hirtle-callaghan-co-llc-takes-176000-position-in-cvs-health-corp-cvs.html.
About CVS Health
CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services.
See Also: Consumer Price Index (CPI)
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.